Return to search

Achieving Medication Safety during Acute Kidney Injury: The Impact of Clinical Decision Support and Real-Time Pharmacy Surveillance

The utilization of clinical decision support (CDS) is increasing among healthcare facilities that have implemented computerized physician order entry or electronic medical records. Formal prospective evaluation of CDS implementations rarely occurs, and misuse or flaws in system design are often not recognized or corrected. Through retrospective nephrologist adjudication of acute kidney injury (AKI) CDS alerts, we identified patient and knowledgebase factors that contributed to inappropriate, or false positive, alerts. We also estimated the rate of inappropriate provider responses, which occurred in the setting of both true and false positive alerts. We found that few alerts were determined to be inappropriate. Unintended adverse consequences, or inappropriate provider responses resulting from inappropriate alerts, were rare.
Retrospective review often occurs too late to make critical corrections or initiate redesign efforts. We developed a real-time, web-based surveillance tool for nephrotoxic and renally cleared medications that integrates provider responses to CDS recommendations with relevant medication ordering, administration, and therapeutic monitoring data. The surveillance view displays all currently admitted, eligible patients and provides brief demographics with triggering order, laboratory, and CDS interactions to facilitate the identification of high-risk patient conditions, such as an imminent adverse drug event (ADE) or potential ADE (pADE). The patient detail view displays a detailed timeline of orders, order administrations, laboratory values, and CDS interactions for an individual patient and allows users to understand provider actions and patient condition changes occurring in conjunction with CDS interactions.
We evaluated the surveillance tool with a randomized trial, where intervention patients were monitored on the surveillance tool daily by a clinical pharmacist and control patients received only existing CDS and standard of care. Despite interventions made by the study pharmacist from the surveillance tool, we found no significant change in the timeliness of provider modifications or discontinuations of targeted medications or occurrence of pADEs or ADEs. We concluded that clinical pharmacist surveillance of AKI-related medication alerts did not improve the timeliness or quality of provider responses or patient outcomes.

Identiferoai:union.ndltd.org:VANDERBILT/oai:VANDERBILTETD:etd-11242010-144036
Date06 December 2010
CreatorsMcCoy, Allison Beck
ContributorsCynthia S. Gadd, John M. Starmer, Lemuel R. Waitman, Bob L. Lobo, Josh F. Peterson
PublisherVANDERBILT
Source SetsVanderbilt University Theses
LanguageEnglish
Detected LanguageEnglish
Typetext
Formatapplication/pdf
Sourcehttp://etd.library.vanderbilt.edu//available/etd-11242010-144036/
Rightsunrestricted, I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to Vanderbilt University or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report.

Page generated in 0.0014 seconds